MetaOptics says it is shifting its strategy toward commercialising metalens technology. Multiple reports state that the company has withdrawn its application to list on the Nasdaq stock market. The company also defers a previously planned U.S. dual listing, indicating it will not proceed on that track at this time. The updates are framed as part of a broader focus on advancing metalens commercialisation. While the sources agree on the key corporate actions—withdrawal of the Nasdaq listing application and postponement of the U.S. dual listing—they provide no additional details in the provided excerpts about the reasons behind the decisions, the specific timeline for any future listing plans, or the next steps for metalens commercialisation. The company’s stated emphasis is on moving metalens technology from development toward commercial deployment. As presented across outlets, the announcements reflect a change in capital market plans while maintaining continuity in the company’s technology focus.